Modulating DDR in GBM to Enable Radiosensitizer-Driven Combination Strategies
• See how VSPharmTech is developing VS-101 to enable radiosensitizer-driven strategies in glioblastoma
• Clarifying synthetic lethality and combination strategies in GBM
• Exploring regulatory and orphan drug designation progress